Apolipoprotein B and interleukin 1 receptor antagonist: reversing the risk of coronary heart disease

Apolipoprotein B and interleukin 1 receptor antagonist: reversing the risk of coronary heart disease

AimsEpidemiological evidence for the link of interleukin 1 (IL-1) and its inhibition with cardiovascular diseases (CVDs) remains controversial. We aim to investigate the cardiovascular effects of IL-1 receptor antagonist (IL-1Ra) and underlying mechanisms.MethodsGenetic variants identified from a ge...

Full description

Bibliographic Details
Main Authors: Fangkun Yang, Ning Huangfu, Jiaxi Shen, Pengpeng Su, Lujie Zhu, Hanbin Cui, Shuai Yuan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Endocrinology
Subjects:
apolipoprotein B
interleukin 1 receptor antagonist
coronary heart disease
myocardial infarction
lifestyle modification
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1278273/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1278273/full

Similar Items